SPRY2 inhibits cell proliferation by acting as a feedback inhibitor of the RAS-MAPK pathway downstream of FGF/FGFR (36), and loss of SPRY2 expression was shown to promote cancer-associated fibroblast activation and BC progression (37). Here, SPRY2 is linked to cancer.